Takeda Pharmaceutical (NYSE:TAK) Insider Sells $235,067.80 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 12,980 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total transaction of $235,067.80. Following the completion of the transaction, the insider directly owned 40,049 shares in the company, valued at $725,287.39. The trade was a 24.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nicola Deidre Petal Greenway also recently made the following trade(s):

• On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $115,835.40.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $18.17 on Friday. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a fifty day moving average of $16.79 and a 200-day moving average of $17.18. The company has a market capitalization of $58.22 billion, a P/E ratio of 53.44 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, July 30th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, equities research analysts predict that Takeda Pharmaceutical Co. will post 1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Concurrent Investment Advisors LLC bought a new stake in shares of Takeda Pharmaceutical in the 2nd quarter valued at about $191,000. Natural Investments LLC grew its position in Takeda Pharmaceutical by 3.6% during the 2nd quarter. Natural Investments LLC now owns 17,230 shares of the company’s stock worth $276,000 after acquiring an additional 596 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in Takeda Pharmaceutical in the 2nd quarter worth approximately $163,000. GAMMA Investing LLC boosted its stake in shares of Takeda Pharmaceutical by 10.7% during the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after purchasing an additional 1,338 shares during the period. Finally, Versant Capital Management Inc grew its holdings in shares of Takeda Pharmaceutical by 10.8% in the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock worth $684,000 after purchasing an additional 4,169 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on TAK shares. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.